Lupin Pharma sees a 'billion dollar' weight-loss drug opportunity in India

Ramesh Swaminathan, Executive Director and CFO of Lupin, says India’s weight-loss drug market could reach $1 billion, and expects Lupin to secure a strong share once semaglutide’s patent expires in March 2026. He also believes that the U.S. won't come out with tariffs on generic medicines and remains bullish on the company's prospects in the country.